Table 2 Prevalence of metabolic syndrome and related conditions across Australian Indigenous and non-Indigenous populations.

From: Metabolic syndrome in Australia: nationwide survey results by remoteness and Indigenous status, 2012–2019

Condition

Population group

Previous surveyc

Latest surveyd

AARC

na

% (95% CI)b

na

% (95% CI)b

 

Metabolic syndrome

Non-Indigenous (NHS)

888

5.5 (5.11, 6.03)

860

4.6 (4.23, 4.99)

−6.07

Indigenous (NATSIHS)

433

4.1 (3.59, 4.7)

597

7.1 (6.19, 8.19)

9.59

• Central obesity

Non-Indigenous (NHS)

6025

39.9 (38.9, 40.98)

7060

40.9 (39.90, 41.85)

0.78

Indigenous (NATSIHS)

4103

55.0 (53.35, 56.66)

3973

57.4 (55.14, 59.63)

0.71

• Type 2 diabetes

Non-Indigenous (NHS)

794

5.0 (4.62, 5.52)

929

4.8 (4.44, 5.21)

−1.61

Indigenous (NATSIHS)

1033

9.8 (8.91, 10.69)

856

9.9 (8.85, 11.06)

0.24

• Hypertension

Non-Indigenous (NHS)

2355

14.6 (13.86, 15.30)

2544

13.7 (13.06, 14.34)

−2.06

Indigenous (NATSIHS)

1112

9.5 (8.68, 10.41)

1106

13.9 (12.53, 15.34)

6.5

• High cholesterol

Non-Indigenous (NHS)

1475

9.1 (8.58, 9.73)

1466

7.8 (7.36, 8.35)

−4.98

Indigenous (NATSIHS)

510

4.7 (4.15, 5.35)

615

7.6 (6.58, 8.67)

8.17

  1. NHS national health survey, NATSIHS National Aboriginal and Torres Strait Islander Health Survey, CI confidence interval, AARC average annual rate of change (negative and positive sign represents a decrease and an increase in the prevalence, respectively).
  2. aUnweighted frequency.
  3. bWeighted estimates.
  4. c2012–2013 and 2014–2015 for Indigenous and Non-Indigenous survey, respectively.
  5. d2018–2019 and 2017–2018 for Indigenous and Non-Indigenous survey, respectively.
Back to article page